Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™

Richard T. Hoppe*, Ranjana Hira Advani, Philip J. Bierman, Clara D. Bloomfield, Francis Buadi, Benjamin Djulgegovic, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Mark S. Kaminski, Gena Love, David G. Maloney, Peter M. Mauch, Joseph O. Moore, Russell J. Schilder, Lawrence Weiss, Jane N. Winter, Joachim Yahalom, Andrew D. Zelenetz

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


The management of HD continues to evolve, and the NCCN guidelines have undergone major changes since their inception. Current management programs are based on comprehensive clinical staging followed by combined modality therapy for patients with favorable and intermediate prognosis, or chemotherapy alone for patients with advanced disease. Relapse is uncommon, but secondary management with peripheral stem cell transplantation may be effective. The excellent prognosis for these patients mandates careful long-term follow-up to detect late treatment effects.

Original languageEnglish (US)
Pages (from-to)210-230
Number of pages21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number3
StatePublished - Mar 2006


  • Classical HD
  • Combined modality therapy
  • Hodgkin disease
  • Lymphocyte predominance
  • Lymphoma
  • NCCN Clinical Practice Guidelines

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™'. Together they form a unique fingerprint.

Cite this